Amarantus Bioscience Holdings Inc (AMBS)

[Shaka_Zulu]

This current press release appears to be old news. I would suggest everyone read, reread, the October 25th press release, which sounds very similar to this latest PR. They've simpy interchanged several key words with other synonyms.

OCT 25TH

"today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson’s disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson’s disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson’s called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not."

Don't be surprised if this sells off. I remain cautious.